Clinical Report: Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer

Overview

Roswell Park Comprehensive Cancer Center presents key findings at ASCO 2026, highlighting the potential benefits of GLP-1 receptor agonists in breast cancer and addressing barriers to CAR T-cell therapy access. The research emphasizes the importance of ongoing evaluation of new therapies and their implications for patient care.

Background

The ASCO annual meeting is a pivotal event for oncologists, providing a platform for the latest research in cancer treatment. This year, Roswell Park's contributions focus on innovative therapies and the challenges in accessing clinical trials. Understanding these developments is crucial for improving patient outcomes in oncology.

Data Highlights

Key Findings

Clinical Implications

The findings suggest that GLP-1 receptor agonists could be considered in the management of overweight/obese patients at risk for breast cancer. Additionally, addressing the accessibility of CAR T-cell therapy is essential for improving treatment options for patients with hematologic malignancies.

Conclusion

The presentations from Roswell Park at ASCO 2026 underscore the need for continued research into new therapies and the importance of addressing barriers to clinical trial access. These efforts are vital for advancing cancer care and improving patient outcomes.

Related Resources & Content

1. FDA, FDA, 2025 -- FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation
2. PubMed, GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity, 2025 -- GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
3. PubMed, Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas, 2025 -- Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas
4. ASCO Post — TAP Homepage - The ASCO Post
5. The ASCO Post — SABCS 2025: High-Level Review of Select Data
6. The ASCO Post — SABCS 2025: High-Level Review of Select Data
7. The ASCO Post — SABCS 2025: High-Level Review of Select Data
8. ASCO Post — TAP Homepage
9. ASCO Post — SABCS 2025: High-Level Review of Select Data
10. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation | FDA
11. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity - PubMed
12. Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas - PubMed